Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABR with Durvalumab and Tremelimumab in Advanced Gynecologic Cancers
NCT03452332Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2018
- Primary completion
- Aug 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab and tremelimumab in Cervical Cancer (CC), vaginal cancer and vulvar cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of adverse events. Started Jul 2018; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
Cervical Cancer (CC)vaginal cancervulvar cancer
Beyond the preview
Go deeper on NCT03452332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03452332.